Aspira Women's Health: Director Changes & Officer Compensation
Ticker: AWHL · Form: 8-K · Filed: Mar 21, 2024 · CIK: 926617
Sentiment: neutral
Topics: director-change, officer-compensation, governance
TL;DR
Aspira Women's Health swapped a director and is talking officer pay.
AI Summary
Aspira Women's Health Inc. announced on March 16, 2024, the departure of Director Dr. Michael J. McNeely and the appointment of Dr. David L. Smith as a new director. The company also reported on compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and unspecified compensatory arrangements can introduce uncertainty regarding company direction and financial commitments.
Key Players & Entities
- Dr. Michael J. McNeely (person) — Departing Director
- Dr. David L. Smith (person) — Appointed Director
- Aspira Women's Health Inc. (company) — Registrant
FAQ
Who is the departing director and when did their departure become effective?
Dr. Michael J. McNeely is the departing director, with the earliest event reported as March 16, 2024.
Who has been appointed as a new director to the board?
Dr. David L. Smith has been appointed as a new director.
What is the primary business of Aspira Women's Health Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]'.
What is the state of incorporation for Aspira Women's Health Inc.?
The state of incorporation is Delaware.
What other items are covered in this 8-K filing besides director changes?
This filing also covers the election of directors and compensatory arrangements of certain officers.
Filing Stats: 1,328 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-03-21 16:10:01
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
- $400,000 — y Ms. Milligan an annual base salary of $400,000. In addition, Ms. Milligan will be elig
Filing Documents
- awh-20240316x8k.htm (8-K) — 83KB
- awh-20240316xex10_1.htm (EX-10.1) — 90KB
- 0000926617-24-000006.txt ( ) — 312KB
- awh-20240316.xsd (EX-101.SCH) — 2KB
- awh-20240316_lab.xml (EX-101.LAB) — 15KB
- awh-20240316_pre.xml (EX-101.PRE) — 11KB
- awh-20240316x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Employment Agreement between Aspira Women's Health Inc. and Sandra Milligan effective April 1, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: March 21, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer